A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Avacincaptad pegol (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors OphthoTech Corporation
- 08 Nov 2017 According to an OphthoTech Corporation media release, based on the anticipated enrollment rate, the Company expects initial top-line data from this trial to be available by the end of 2018.
- 19 Sep 2017 Status changed from planning to recruiting, according to an OphthoTech Corporation media release.
- 31 Jul 2017 New trial record